Issue Date: September 28, 2009
New Technology Bows At Seattle Genetics
Seattle Genetics, a biotech firm known for its antibody-drug conjugate platform, has come up with a new technology that increases the potency of monoclonal antibodies. The company’s sugar-engineered antibody technology prevents fucose from being incorporated into the carbohydrate chains of monoclonal antibodies, making the drugs better at evoking an immune response. Adding these modified sugars to cell-culture media doesn’t change the antibody manufacturing process, yield, or product quality. The new technology will be incorporated into Seattle Genetics’ early-stage pipeline and could be partnered with other companies.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society